* Allovir Inc is expected to show no change in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Allovir Inc is for a loss of 9 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 1.6% in the last three months.
* Wall Street's median 12-month price target for Allovir Inc is $0.95, above its last closing price of $0.85.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.07 -0.10 -0.05 Beat 52.4
Mar. 31 2024 -0.17 -0.16 -0.26 Missed -66
Dec. 31 2023 -0.46 -0.43 -0.36 Beat 15.9
Sep. 30 2023 -0.41 -0.42 -0.39 Beat 6.3
Jun. -0.43 -0.45 -0.48 Missed -6.7
30 2023
Mar. 31 2023 -0.46 -0.46 -0.44 Beat 5.4
Dec. 31 2022 -0.56 -0.54 -0.37 Beat 31.9
Sep. 30 2022 -0.52 -0.53 -0.50 Beat 5.1
This summary was machine generated October 29 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。